Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Quillivant · 1 trial · 1 indication
The SKAMP scale measures the manifestations of attention deficit hyperactivity disorder (ADHD) using an independent observer rating of the participant's impairment in classroom observed behaviors. SKAMP combined score is comprised of 13 items (including subscales: attention with items 1-4, deportment with items 5-8, quality of work with items 9-11 and compliance with items 12-13). The SKAMP composite score was obtained by summing up each item score where each item is rated on a 7-point impairment scale (0=normal to 6=maximal impairment) for a total possible combined score of 0 to 78; where higher score signified worst impairment.
| Arm | Type | Description |
|---|---|---|
| Active | EXPERIMENTAL | - |
| Comparator | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Quillivant Oral Suspension XR | DRUG | Oral Suspension 25mg/5mL; 20-60 mg/day |
| Placebo | DRUG | Matching Placebo Oral Suspension 25mg/5mL; 20-60 mg/day |
Inclusion Criteria: * Male or female from 6 to 12 years of age at the time of screening, inclusive. * Diagnosis of ADHD by a Psychiatrist, Psychologist, Developmental Pediatrician, or a Pediatrician meeting diagnostic criteria for ADHD (DSM-IV). A Schedule for Affective Disorders and Schizophrenia ...
Quillivant is a small molecule medication used for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). It is being developed by Pfizer, Inc. and is currently in Phase 3 clinical development. Quillivant is an oral suspension formulation intended to manage symptoms of ADHD.
Quillivant is being developed by Pfizer, Inc., a pharmaceutical company listed on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in Phase 3 clinical development for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).
Quillivant is in Phase 3 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. The drug is being studied for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in a completed Phase 3 clinical trial.
Quillivant has one completed Phase 3 clinical trial registered under NCT00904670. This trial, titled 'Quillivant Oral Suspension (Quillivant XR) in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD)', was a randomized, double-blind, placebo-controlled study conducted in the United States with 45 participants aged 6 years and older.
Yes, Quillivant is also known as Quillivant XR. The clinical trial NCT00904670 specifically refers to the drug as 'Quillivant Oral Suspension (Quillivant XR)'. This alternative name is used in the context of the extended-release oral suspension formulation being studied for ADHD.